Table 2.
GMTs for anti-HPV types 16 and 18 in survivors of cancer versus the general population, by subgroup
|
Survivors of cancer |
General population |
Survivors vs general population |
||||||
|---|---|---|---|---|---|---|---|---|
| n | GMT (95% CI), mMU/mL | GMT (95% CI), IU/mL* | n | GMT (95% CI), mMU/mL | GMT (95% CI), IU/mL* | Ratio of GMT (multiplicity-adjusted 95% CI) | ||
| HPV4 | ||||||||
| Female participants aged 9–15 years | ||||||||
| Anti-HPV type 16 | 51 | 15 209·7 (10 152·4–20 267·1) | 2083·7 (1390·9–2776·6) | 915 | 4918·5 (4556·6–5309·1) | 673·8 (624·3–727·4) | 3·09 (1·76–4·52) | |
| Anti-HPV type 18 | 54 | 2638·3 (1792·5–3484·1) | 496·0 (337·0–655·0) | 922 | 1042·6 (967·6–1123·3) | 196·0 (181·9–211·2) | 2·53 (1·48–3·66) | |
| Male participants aged 9–15 years | ||||||||
| Anti-HPV type 16 | 65 | 16 134·6 (11 944·7–20 324·5) | 2210·4 (1636·4–2784·5) | 882 | 6056·5 (5601·3–6548·7) | 829·7 (767·4–897·2) | 2·66 (1·75–3·66) | |
| Anti-HPV type 18 | 66 | 3472·2 (2407·9–4536·5) | 652·8 (452·7–852·9) | 887 | 1357·4 (1249·4–1474·7) | 255·2 (234·9–277·2) | 2·56 (1·52–3·68) | |
| Female participants aged 16–26 years | ||||||||
| Anti-HPV type 16 | 28 | 6107·3 (3149·1–9065·5) | 836·7 (431·4–1242·0) | 3249 | 2409·2 (2309·0–2513·8) | 330·1 (316·3–344·4) | 2·53 (1·00–4·09) | |
| Anti-HPV type 18 | 30 | 1009·6 (582·9–1436·3) | 189·8 (109·6–270·0) | 3566 | 475·2 (458·8–492·1) | 89·4 (86·3–92·5) | 2·12 (1·00–3·26) | |
| Male participants aged 16–26 years | ||||||||
| Anti-HPV type 16 | 65 | 8740·0 (6000·6–11 479·5) | 1197·4 (822·1–1572·7) | 1136 | 2403·3 (2243·4–2574·6) | 329·3 (307·4–352·7) | 3·64 (2·15–5·21) | |
| Anti-HPV type 18 | 68 | 1920·0 (1210·2–2629·9) | 361·0 (227·5–494·4) | 1175 | 402·6 (374·6–432·7) | 75·7 (70·4–81·3) | 4·77 (2·48–7·18) | |
| HPV9 | ||||||||
| Female participants aged 9–15 years | ||||||||
| Anti-HPV type 16 | 41 | 11 763·6 (8826·8–14 700·4) | NA | 2405 | 7159·9 (6919·7–7408·5) | NA | 1·64 (1·12–2·18) | |
| Anti-HPV type 18 | 41 | 3457·2 (2545·0–4369·4) | NA | 2420 | 2085·5 (2002·2–2172·3) | NA | 1·66 (1·10–2·23) | |
| Male participants aged 9–15 years | ||||||||
| Anti-HPV type 16 | 53 | 16 419·6 (11 743·7–21 095·5) | NA | 1076 | 8444·9 (8054·2–8854·5) | NA | 1·94 (1·23–2·68) | |
| Anti-HPV type 18 | 50 | 5559·8 (4081·9–7037·7) | NA | 1074 | 2620·4 (2474·3–2775·2) | NA | 2·12 (1·39–2·89) | |
| Female participants aged 16–26 years | ||||||||
| Anti-HPV type 16 | 23 | 11 522·9 (6301·3–16 744·5) | NA | 4361 | 3159·0 (3088·6–3231·1) | NA | 3·65 (1·61–5·70) | |
| Anti-HPV type 18 | 28 | 3483·3 (408·6–6557·9) | NA | 4884 | 809·9 (789·2–831·1) | NA | 4·30 (0·00–9·05) | |
| Male participants aged 16–26 years | ||||||||
| Anti-HPV type 16 | 32 | 10 770·4 (6127·8–15 412·9) | NA | 899 | 3346·0 (3158·9–3544·1) | NA | 3·22 (1·46–5·02) | |
| Anti-HPV type 18 | 32 | 3013·4 (1685·1–4341·6) | NA | 906 | 808·2 (754·9–865·4) | NA | 3·73 (1·65–5·89) | |
Anti-HPV type 16 and 18 GMTs with 95% CIs for cancer survivors and general population comparisons who received the HPV4 and HPV9 vaccines, with corresponding ratios and multiplicity-adjusted 95% CI. GMT=geometric mean titres. mMU=milli-Merck units. IU=international units. NA=not available.
*
There are no available conversion factors from mMU/mL to IU/mL for anti-HPV types 16 and 18 for the nonavalent competitive Luminex immunoassays performed in the HPV9 vaccine cohort.